Eli Lilly and Company

Chetankumar Natvarlal Patel

Julian Davies

Catherine Brautigam Beidler

Robert Jan Benschop

Stephanie Marie Truhlar

Michael Parvin Johnson

Angela Jeannine Okragly

Oliver Schroeder

Daniel Scott Girard

Andrea Paula Martin

Fabio Magrini

Neelufar Mozaffarian

Antibodies to human pituitary adenylate cyclase-activating peptide, compositions comprising such antibodies, and methods of using such antibodies for the treatment of pain including headache and/or migraine.

Anti-PACAP antibody

Antibodies which bind and neutralize human IL-33, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with allergic disease including treating atopic dermatitis.

DNA molecules encoding anti-IL-33 antibodies

Antibodies to tropomysin receptor kinase (TrkA), compositions including such antibodies, and methods of using such antibodies for the treatment of pain including post-surgical pain, rheumatoid arthritis pain, neuropathic pain and osteoarthritis pain.

Anti-TrkA antibody

Anti-IL-33 antibodies and uses thereof for disease treatment

The invention relates to engineered, humanized antibodies that have high binding affinity for and neutralize human IL-21, methods of using the antibodies to treat conditions in which antagonism or neutralization of the effects of IL-21 is warranted, such as autoimmune conditions, compositions and methods for recombinantly producing the antibodies, and pharmaceutical compositions comprising the antibodies.

IL-21 antibodies and methods of making or using the antibodies

Growing community of inventors

Fishers, IN, United States of America

Chetankumar Natvarlal Patel